替罗非班在急性缺血性脑卒中的应用现状及研究进展.

Anti-platelet therapy is the basic strategy for the prevention and treatment of ischemic stroke. Aspirin plays an anti-platelet aggregation role by inhibiting TXA2 pathway, while thiopyridine drugs such as clopidogrel and ticagrelor play an anti-platelet aggregation role by inhibiting ADP pathway. Both of these pathways play a role in the upstream pathway of platelet aggregation, while platelet glycoprotein (GP) IIb/II a receptor is the final pathway of platelet aggregation and thrombosis, and the antagonists can quickly exert their anti-platelet aggregation effects by directly binding to GP II b/ II a receptors.. Tirofiban is the main GP IIb/Il a receptor antagonist used in clinic in China at present, and its application in cardiovascular field and coronary intervention therapy has also been recommended by authoritative guidelines for coronary atherosclerotic heart disease at home and abroad. However, the application of tirofiban in cerebrovascular diseases is still in the exploratory stage, lacking the support of large-scale clinical trial data, and it belongs to off-label drug use. This paper reviewed the application status and research progress of tirofiban in acute ischemic stroke based on the relevant literature at home and abroad in recent five years. [ABSTRACT FROM AUTHOR]